The proportion of positive PD-L1 expression was slightly higher in NEC (TPS: 28.6%; IPS: 42.9%) than in ATC (TPS: 20.5%; IPS: 34.1%) in this T-NEN cohort, which is in line with a previous finding that the more aggressive the NEN, the higher the expression of PD-L1 (28). The gene discussed is CD274; the disease is neuroendocrine carcinoma.